Clinical Observation of Recombinant Human Vascular Endostatin Durative Transfusion Combined with Window Period Arterial Infusion Chemotherapy in the Treatment of Advanced Lung Squamous Carcinoma
10.3779/j.issn.1009-3419.2015.08.05
- VernacularTitle:重组人血管内皮抑制素静脉持续泵入联合窗口期动脉灌注化疗治疗晚期肺鳞癌的临床观察
- Author:
LV YUAN
1
;
JIANG RONG
;
MA CHUNHUA
;
LI JINDUO
;
WANG BIN
;
SUN LIWEI
;
MU NING
Author Information
1. 300060天津，天津市环湖医院肿瘤介入科，天津市脑血管与神经变性重点实验室
- Keywords:
Lung neoplasms;
Recombinant human vascular endostatin;
Arterial infusion chemotherapy;
Adverse reactions
- From:
Chinese Journal of Lung Cancer
2015;(8):500-504
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Lung cancer is one of the most common malignant tumors in China. hTe aim of this study is to observe the effcacy and safety of recombinant human vascular endostatin (endostar) durative transfusion combined with window period arterial infusion chemotherapy in the treatment of advanced lung squamous carcinoma.Meth-ods From February 2014 to January 2015, 10 cases of the cytological or histological pathology diagnosed stage IIIb - stage IV lung squamous carcinoma were treated with recombinant human vascular endostatin (30 mg/d) durative transfusion combined with window period arterial infusion chemotherapy. Over the same period of 10 cases stage IIIb - stage IV lung squamous carci-noma patients for pure arterial perfusion chemotherapy were compared. Recombinant human vascular endostatin was durative transfused every 24 hours for 7 days in combination group, and in the 4th day of window period, the 10 patients were received artery infusion chemotherapy, using docetaxel combined with cisplatin. Pure treatment group received the same arterial perfu-sion chemotherapy regimen. 4 weeks was a cycle. 4 weeks atfer 2 cycles, to evaluate the short-term effects and the adverse drug reactions.Results 2 groups of patients were received 2 cycles treatments. hTe response rate (RR) was 70.0%, and the disease control rate (DCR) was 90.0% in the combination group; In the pure treatment group were 50.0%, 70.0% respectively, there were no statistically signiifcant difference (P=0.650, 0.582). hTe adverse reactions of the treatment were mild, including level 1-2 of gastrointestinal reaction and blood toxicity, there were no statistically signiifcant difference (P=0.999,P=0.628). In the combination group, 1 patient occurred level 1 of cardiac toxicity.Conclusion Recombinant human vascular endostatin dura-tive transfusion combined with window period arterial infusion chemotherapy in the treatment of advanced lung squamous carcinoma could take a signiifcant curative effect, and the patients were well tolerated by the mild adverse reactions.
